Hodgkin disease
Drug research and approvals for hodgkin disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,011 studies of hodgkin disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 1,011
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Multimodal Ultrasound for Lymphoma Classification and Treatment Response PredictionNCT07941063 · Not reported · Chinese PLA General Hospital · starts Jan 1, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational StudyNCT07895927 · Not reported · University Hospital, Strasbourg, France · starts Feb 11, 2026
Approved 12
- Brentuximab vedotinTubulin inhibitor
- DacarbazineDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- VinblastineTubulin inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- CyclophosphamideDNA inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- BleomycinDNA inhibitor
- CarmustineGlutathione reductase inhibitor
- ChlorambucilDNA inhibitor
- LomustineDNA inhibitor
- ThiotepaDNA inhibitor
Phase 3 12 of 29
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PrednisoneGlucocorticoid receptor agonist
- BendamustineDNA inhibitor
- IfosfamideDNA inhibitor
- VincristineTubulin inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- TacrolimusFK506-binding protein 1A inhibitor
- CarboplatinDNA inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- VinorelbineTubulin inhibitor
Phase 2 12 of 62
- Bortezomib26S proteasome inhibitor
- BusulfanDNA inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Fludarabine
- VorinostatHistone deacetylase 1 inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- 2-mercaptoethanesulfonic acid
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- EverolimusFK506-binding protein 1A inhibitor
- OxaliplatinDNA inhibitor
Phase 1 or earlier 12 of 38
- RomidepsinHistone deacetylase inhibitor
- PaclitaxelTubulin inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- GivinostatHistone deacetylase inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- IsotretinoinRetinoic acid receptor agonist
- Pentetic acidRadioactive metals chelating agent
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- Yttrium y 90 ibritumomab tiuxetanB-lymphocyte antigen CD20 binding agent
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
How its trials ended
818 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 242 whose ending is known, 48% met their primary endpoint, 3% missed it and 50% stopped early.
- Completed, result not reported33140%
- Ongoing17822%
- Met its primary endpoint11514%
- Status unknown678%
- Stopped: other or unclear547%
- Stopped: enrollment or feasibility354%
- Stopped: sponsor or business decision182%
- Missed its primary endpoint71%
- Stopped: funding71%
- Stopped: lack of efficacy51%
- Stopped: safety1<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 18, 2018 | Carmustine medac (previously Carmustine Obvius)Carmustine · generic | medac Gesellschaft für klinische Spezialpräparate mbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA